Pivekimab sunirine-pvzy (Decnupaz)
Reconstitution and dilutionFull monograph review pending
U.S. label preparation
Decnupaz · Reconstitution and dilution
- Preparation
- Add 1.1 mL sterile water for injection to each vial (2 mg/mL). Add 4.8 mL of 5% dextrose to the vial (0.4 mg/mL). Transfer the prescribed dose volume and combine with an equal volume of 5% dextrose in a second syringe (0.2 mg/mL).
- Administration and handling
- Use the labeled syringe technique. Avoid an in-line filter if possible. When required, the label permits a 1.2-micron PES filter.
- Manufacturer's storage limits
- If preparation pauses after reconstitution, refrigerate for up to 4 hours at 2-8 C. For the diluted syringe, the total time from reconstitution through infusion completion is limited to 24 hours, including no more than 8 hours at 9-25 C. Refrigerate at 2-8 C for the refrigerated portion. Do not freeze. A compounding beyond-use date requires a separate assessment.
Product and source details
AbbVie Inc. · BLA761460
Product NDC: 0074-0282
SPL effective 2026-05-27 | SPL version 2. Checked 2026-11-13.
Source for this summary: U.S. prescribing information. Use the full label for dose selection, contraindications, preparation tables and monitoring.
Product identifiers and clinical review status
U.S. label preparation available. Full monograph review pending.
Exact formulation, concentration, container, manufacturer, regulatory identifiers, and a reproducible label snapshot have not all been reconciled.
What remains to be completed
- Obtain independent corroboration of the label preparation where available.
- Complete indication- and age-specific dosing, incompatibility, monitoring and stability review.
- Assess any proposed compounding BUD for the exact formulation, concentration, container and conditions.